219 related articles for article (PubMed ID: 35156714)
1. Oncolytic virus treatment differentially affects the CD56
Wantoch M; Wilson EB; Droop AP; Phillips SL; Coffey M; El-Sherbiny YM; Holmes TD; Melcher AA; Wetherill LF; Cook GP
Immunology; 2022 May; 166(1):104-120. PubMed ID: 35156714
[TBL] [Abstract][Full Text] [Related]
2. CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.
Yu J; Mao HC; Wei M; Hughes T; Zhang J; Park IK; Liu S; McClory S; Marcucci G; Trotta R; Caligiuri MA
Blood; 2010 Jan; 115(2):274-81. PubMed ID: 19897577
[TBL] [Abstract][Full Text] [Related]
3. Distinct natural killer cells in HIV-exposed seronegative subjects with effector cytotoxic CD56(dim) and CD56(bright) cells and memory-like CD57⁺NKG2C⁺CD56(dim) cells.
Lima JF; Oliveira LM; Pereira NZ; Mitsunari GE; Duarte AJ; Sato MN
J Acquir Immune Defic Syndr; 2014 Dec; 67(5):463-71. PubMed ID: 25230289
[TBL] [Abstract][Full Text] [Related]
4. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
5. Killer Ig-like receptor (KIR) genotype predicts the capacity of human KIR-positive CD56dim NK cells to respond to pathogen-associated signals.
Korbel DS; Norman PJ; Newman KC; Horowitz A; Gendzekhadze K; Parham P; Riley EM
J Immunol; 2009 May; 182(10):6426-34. PubMed ID: 19414796
[TBL] [Abstract][Full Text] [Related]
6. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A.
Nielsen N; Ødum N; Ursø B; Lanier LL; Spee P
PLoS One; 2012; 7(2):e31959. PubMed ID: 22384114
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1beta costimulates interferon-gamma production by human natural killer cells.
Cooper MA; Fehniger TA; Ponnappan A; Mehta V; Wewers MD; Caligiuri MA
Eur J Immunol; 2001 Mar; 31(3):792-801. PubMed ID: 11241284
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-21 differentially affects human natural killer cell subsets.
Wendt K; Wilk E; Buyny S; Schmidt RE; Jacobs R
Immunology; 2007 Dec; 122(4):486-95. PubMed ID: 17635612
[TBL] [Abstract][Full Text] [Related]
10. CD56
Judge CJ; Kostadinova L; Sherman KE; Butt AA; Falck-Ytter Y; Funderburg NT; Landay AL; Lederman MM; Sieg SF; Sandberg JK; Anthony DD
J Leukoc Biol; 2017 Jul; 102(1):171-184. PubMed ID: 28400540
[TBL] [Abstract][Full Text] [Related]
11. CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.
Lin AW; Gonzalez SA; Cunningham-Rundles S; Dorante G; Marshall S; Tignor A; Ha C; Jacobson IM; Talal AH
Clin Exp Immunol; 2004 Aug; 137(2):408-16. PubMed ID: 15270860
[TBL] [Abstract][Full Text] [Related]
12. Human natural killer cell maturation defect supports in vivo CD56(bright) to CD56(dim) lineage development.
Domaica CI; Fuertes MB; Uriarte I; Girart MV; Sardañons J; Comas DI; Di Giovanni D; Gaillard MI; Bezrodnik L; Zwirner NW
PLoS One; 2012; 7(12):e51677. PubMed ID: 23240056
[TBL] [Abstract][Full Text] [Related]
13. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Huth TK; Staines D; Marshall-Gradisnik S
J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
[TBL] [Abstract][Full Text] [Related]
14. Differential alteration of CD56(bright) and CD56 (dim) natural killer cells in frequency, phenotype, and cytokine response in chronic hepatitis C virus infection.
Miyagi T; Shimizu S; Tatsumi T; Nishio K; Hiramatsu N; Kanto T; Hayashi N; Takehara T
J Gastroenterol; 2011 Aug; 46(8):1020-30. PubMed ID: 21559771
[TBL] [Abstract][Full Text] [Related]
15. Low-frequency, exhausted immune status of CD56
Pan Z; Zhao R; Shen Y; Liu K; Xue W; Liang C; Peng M; Hu P; Chen M; Xu H
Int Immunopharmacol; 2021 Dec; 101(Pt B):108369. PubMed ID: 34844872
[TBL] [Abstract][Full Text] [Related]
16. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation.
De Maria A; Bozzano F; Cantoni C; Moretta L
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):728-32. PubMed ID: 21187373
[TBL] [Abstract][Full Text] [Related]
17. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals.
Tarazona R; Casado JG; Delarosa O; Torre-Cisneros J; Villanueva JL; Sanchez B; Galiani MD; Gonzalez R; Solana R; Peña J
J Clin Immunol; 2002 May; 22(3):176-83. PubMed ID: 12078859
[TBL] [Abstract][Full Text] [Related]
18. Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells.
Takahashi E; Kuranaga N; Satoh K; Habu Y; Shinomiya N; Asano T; Seki S; Hayakawa M
Scand J Immunol; 2007 Feb; 65(2):126-38. PubMed ID: 17257217
[TBL] [Abstract][Full Text] [Related]
19. Differential IFN-γ production by adult and neonatal blood CD56+ natural killer (NK) and NK-like-T cells in response to Trypanosoma cruzi and IL-15.
Guilmot A; Carlier Y; Truyens C
Parasite Immunol; 2014 Jan; 36(1):43-52. PubMed ID: 24102464
[TBL] [Abstract][Full Text] [Related]
20. Interferon-γ production by tubulointerstitial human CD56
Law BMP; Wilkinson R; Wang X; Kildey K; Lindner M; Rist MJ; Beagley K; Healy H; Kassianos AJ
Kidney Int; 2017 Jul; 92(1):79-88. PubMed ID: 28396119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
